Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Growth Stocks To Follow Now – October 24th
02:39am, Sunday, 26'th Oct 2025
Prologis, Ascendis Pharma A/S, Teledyne Technologies, Pattern Group, and Canopy Growth are the five Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are share
COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency
Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025
04:01pm, Tuesday, 02'nd Sep 2025
COPENHAGEN, Denmark, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR 20
Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference
04:01pm, Thursday, 28'th Aug 2025
COPENHAGEN, Denmark, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the 2025 Wells Fargo Healthcare
Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call Transcript
02:46am, Saturday, 09'th Aug 2025
Ascendis Pharma A/S (ASND) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Jan Moller Mikkelsen - President, CEO, Member of Executive Board & Executive Director Jay Don
Ascendis Pharma Reports Second Quarter 2025 Financial Results
04:01pm, Thursday, 07'th Aug 2025
– Q2 2025 revenue of €103.0 million for YORVIPATH ® and €50.7 million for SKYTROFA ® – TransCon ® CNP (navepegritide) NDA under Priority Review for the treatment of children with achondropl
Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
04:01pm, Thursday, 31'st Jul 2025
COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday
FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
07:00am, Monday, 28'th Jul 2025
First of many planned label expansions supporting Vision 2030 goal to become the leading endocrinology rare disease company On track to initiate basket trial for ISS, SHOX deficiency, Turner syndrome,
Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade
10:56am, Wednesday, 16'th Jul 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 29.8% in Ascendis Pharma (ASND). While the effectiveness of this highly sought-after metric is questionable, th
COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with T
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025
04:01pm, Monday, 07'th Jul 2025
COPENHAGEN, Denmark, July 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held Ju
- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26
FDA Accepts TransCon® CNP NDA for Priority Review
08:00am, Monday, 02'nd Jun 2025
– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo
Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
06:00am, Tuesday, 20'th May 2025
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / May 20, 2025 / Cerrado Gold Inc. ("Cerrado") (TSXV:CERT)(OTCQX:CRDOF) and Asce
COPENHAGEN, Denmark, May 13, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal Approa
